Standardized sTudy With Almotriptan in eaRly Treatment of Migraine (START)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00725140
Recruitment Status : Completed
First Posted : July 30, 2008
Last Update Posted : June 1, 2015
Information provided by (Responsible Party):
Almirall, S.A.

Brief Summary:
This is a observational, open, prospective, single arm cohort study within authorized SPC conditions to describe the effectiveness of Almotriptan in treating acute migraine attacks when pain is mild and in the first hour of pain in everyday primary care clinical practice.

Condition or disease

Detailed Description:

Primary Objective:

To describe the effectiveness of Almotriptan in treating acute migraine attacks when pain is mild and in the first hour of pain in everyday primary care clinical practice.

Secondary Objectives:

  1. Influence of an educational intervention on the early intake of the treatment
  2. Influence of medication history or concomitant medication on treatment results
  3. Influence of migraine triggers on treatment results
  4. Influence of stress on treatment results
  5. Tolerability profile validation
  6. Patients' satisfaction
  7. Reasons for delaying migraine treatment intake

Study Type : Observational
Actual Enrollment : 501 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Standardized sTudy With Almotriptan in eaRly Treatment of Migraine, START. An International, Open-label, Single Arm, Effectiveness and Safety Study of Almotriptan in Primary Care Setting
Study Start Date : June 2008
Actual Primary Completion Date : April 2009
Actual Study Completion Date : July 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Migraine
U.S. FDA Resources


Primary Outcome Measures :
  1. Pain Free [ Time Frame: 2 h from intake ]

Secondary Outcome Measures :
  1. Sustained Pain Free [ Time Frame: 24 h ]
  2. SNAE (Sustained pain free and No Adverse Events) [ Time Frame: 24 h ]
  3. Relapse [ Time Frame: 24 h ]
  4. Second tablet / rescue medication use [ Time Frame: 24 h ]
  5. Associated symptoms presence evolution: Nausea, Vomiting, Photophobia, Phonophobia. [ Time Frame: Basal - 2h - 24h ]
  6. Migraine attack duration [ Time Frame: 24 h ]
  7. Time loss (functional disability) [ Time Frame: 24 h ]
  8. Patients' satisfaction: [ Time Frame: Basal - After each attack ]
  9. Adverse Events [ Time Frame: From recruitment to study end or AE resolution ]
  10. Consistency of response to treatment between attacks (2 h PF in 2/3 attacks) [ Time Frame: 2 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Following SPC conditions and study requirements, male or female of 18 to 65 years old with a minimum of one year of migraine history (International Headache Society criteria, see criteria attached in the protocol Annex 1) of moderate or severe intensity and with a frequency of 2 to 6 attacks per month for the past 3 months.

Inclusion Criteria:

  1. History of a confirmed diagnosis of migraine that meets the IHS diagnosis criteria of migraine with or without aura for at least one year.
  2. Patients with a history of migraine headaches progressing from mild to at least moderate pain intensity if untreated on a scale of no pain (0), mild (1), moderate (2), or severe (3) within the past year.
  3. Migraine headache frequency of 2 to 6 per month for the past 3 months.
  4. Male or female aged 18 to 65 years.
  5. Able to differentiate a migraine headache from an interval (e.g., tension-type) headache.

8.Female patients of childbearing potential must not suspect to be pregnant and have an effective method of birth control for at least 30 days prior to study entry and throughout the study.

11.After full explanation, patients must have signed an informed consent document indicating that they understand the purpose of and the procedures required for the study and are willing to participate in the study.

12.Patients must either use Almotriptan for their migraine acute attacks treatment or prove through the ANAES scale in the basal visit that a change in their treatment approach is required.

Exclusion Criteria:

  1. Patients, who in the opinion of the investigator, should not be enrolled in the study because of the precautions, warnings or contraindications sections of the Almotriptan Summary of Product Characteristics.
  2. Patients who have had 15 or more headache days per month in the previous 6 months (chronic daily headache), or patients having a migraine headache frequency of more than 6 per month for the past 3 months.
  3. Patients with onset of migraine after age 50.
  4. Patients who routinely experience any other type of headache that would confound discrimination from a migraine.
  5. Patients who have exclusively migraine aura without headache.
  6. Patients who typically experience vomiting with their headaches.
  7. Patients with hemiplegic or basilar type migraines.
  8. Patients who typically have headaches that occur predominantly upon awakening in the morning.
  9. Patients who have previously discontinued Almotriptan therapy due to an adverse event or lack of efficacy.

11.Patients taking any of the prohibited concomitant medications listed in Section 10.3.1 of the protocol.

12.Patients who have used any of the following medications within 7 days of study entry and during the trial: sustained release opioids and/or semi-synthetic or long acting opioids.

16.Women who are pregnant or lactating.

18.Patients who have received an investigational drug or used an investigational device within 30 days of study entry.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00725140

28 GPs across France
Diverse, France
26 GPs across Italy
Diverse, Italy
26 GP practices across Spain
Diverse, Spain
Sponsors and Collaborators
Almirall, S.A.
Study Chair: Michel Lanteri-Minet, Dr Pain Evaluation and Treatment Department, Hopital Pasteur, Nice, France

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Almirall, S.A. Identifier: NCT00725140     History of Changes
Other Study ID Numbers: M/31416/51
EudraCT: 2007-003392-39
Spanish AEM: ALM-ALM-2008-01
First Posted: July 30, 2008    Key Record Dates
Last Update Posted: June 1, 2015
Last Verified: May 2015

Keywords provided by Almirall, S.A.:
Early intervention
Primary Care

Additional relevant MeSH terms:
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Serotonin Receptor Agonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs